GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
GSK says asthma and nasal polyps therapy under EU review
GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...
GSK and University of Oxford partner for cancer vaccine research
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
EuropaWire2d
GSK and University of Oxford Launch Cancer Prevention Research Program with £50 Million Investment
GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...
GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme
GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...
GSK announces EMA to review the regulatory application of Shingrix
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...